Zentalis Q4 2020 Earnings Report
Key Takeaways
Zentalis Pharmaceuticals reported a net loss of $40.4 million for the fourth quarter of 2020, compared to a net loss of $14.5 million for the same period in 2019. As of December 31, 2020, the company had cash, cash equivalents, and marketable securities of $338.5 million.
Initiated multiple early-stage clinical trials evaluating ZN-c5, ZN-c3, and ZN-d5.
Announced strategic collaboration with Tempus to expand and strengthen research and development capabilities.
Zentera Therapeutics submitted two Investigational New Drug (IND) applications in China ahead of schedule.
Presenting clinical data from the Phase 1 monotherapy trial of ZN-c3 at the upcoming AACR 2021 Annual Meeting.
Zentalis
Zentalis
Forward Guidance
Zentalis expects that its existing cash, cash equivalents and marketable securities will enable the Company to fund its operating expenses and capital expenditure requirements into 2023.